How should tranexamic acid be used (dose, route, monitoring, contraindications) to treat melasma in adult women of child‑bearing age without clotting disorders?

Tranexamic Acid for Melasma Management

Tranexamic acid is an effective treatment for melasma in adult women of childbearing age without clotting disorders, with oral administration (250 mg twice daily for 12 weeks) showing the most robust efficacy, though intradermal injection (4 mg/mL) offers a viable alternative with localized action and fewer systemic concerns.

Route Selection and Dosing

Oral Tranexamic Acid (First-Line for Refractory Cases)

• Dose: 250 mg twice daily (500 mg total daily) for 12 weeks 1, 2, 3
• Efficacy: Produces the most substantial reduction in MASI scores, with good to very good response (>50% improvement) in approximately 95% of patients by 24 weeks 1, 4
• Advantages: Convenient administration, well-established efficacy even at low doses
• Considerations: May cause GI upset and menstrual irregularities; requires careful patient screening

Intradermal Injection

• Dose: 4 mg/mL diluted in saline, injected intradermally at 1 cm intervals, maximum 8-16 mg per session 5
• Frequency: Monthly sessions for 3-5 treatments, followed by 3-month follow-up 5
• Efficacy: Produces significant MASI score reduction (approximately 50-70% improvement), though recent evidence suggests PRP may be superior 5
• Advantages: Localized action avoids systemic side effects; no thromboembolic risk
• Disadvantages: Mildly painful, requires multiple clinic visits

Topical Application

• Efficacy: Least effective as monotherapy but can be combined with other treatments 6, 7
• Better tolerated than hydroquinone with fewer irritation concerns 6

Critical Contraindications (FDA Label Requirements)

Absolute contraindications 8:

• Active intravascular clotting or thromboembolic disease
• History of thromboembolic events (DVT, PE, stroke, MI)
• Subarachnoid hemorrhage
• Hypersensitivity to tranexamic acid

Avoid concomitant use with 8:

• Hormonal contraceptives (combined oral contraceptives, patches, rings)
• Factor IX concentrates
• Anti-inhibitor coagulant concentrates
• Any pro-thrombotic medications

Patient Screening Protocol

Before initiating oral TXA, screen for:

• Personal or family history of venous or arterial thromboembolism
• Current medications: Specifically hormonal contraceptives (must discontinue or use alternative)
• Cardiovascular risk factors: Smoking, hypertension, diabetes, obesity
• Renal function: Adjust dose if creatinine >1.36 mg/dL 8
• Pregnancy status: While not absolutely contraindicated, data are limited 8

Monitoring Requirements

For Treatment >3 Months

• Ophthalmologic monitoring: Visual acuity and optical coherence tomography at regular intervals 8
• Rationale: Animal studies showed retinal degeneration at high doses, though not observed in humans treated up to 8 years

Routine Monitoring

• No routine laboratory monitoring required for standard melasma treatment duration (12 weeks) 2, 3
• Renal function: Check if baseline creatinine elevated or risk factors present
• Clinical assessment: Evaluate for signs of thrombosis (leg pain/swelling, chest pain, neurologic symptoms)

Treatment Algorithm

1. First-line: Oral TXA 250 mg twice daily for 12 weeks in patients without contraindications 1, 2, 3

   • Screen thoroughly for thromboembolic risk factors
   • Discontinue hormonal contraceptives; use barrier methods
   • Counsel on strict sun protection and maintenance therapy

2. Alternative for patients with contraindications to oral therapy: Intradermal TXA 4 mg/mL monthly for 3-5 sessions 5, 9

   • No systemic absorption concerns
   • Suitable for women requiring hormonal contraception

3. Combination therapy: TXA plus 4% hydroquinone shows superior efficacy 10

   • Consider for severe or refractory cases
   • Intradermal TXA combined with topical hydroquinone demonstrated best outcomes

4. Maintenance: Melasma requires chronic management with regular follow-ups 5

   • Relapse is uncommon but can occur (5% at 24 weeks) 1
   • Emphasize sun protection and appropriate skincare routine

Safety Profile

Common adverse effects (oral route) 1, 2, 6:

• GI upset (nausea, diarrhea) - dose-dependent, may resolve with reduction
• Menstrual irregularities
• Mild and transient

Intradermal injection side effects 5, 9:

• Injection-site pain and erythema
• Self-limiting, no serious adverse events reported

Critical safety note: Despite theoretical thromboembolic concerns, studies demonstrate TXA does not increase thrombotic risk when used appropriately in screened patients 2, 3. However, the FDA label clearly warns against use with hormonal contraceptives and in patients with active clotting 8.

Key Clinical Pitfalls

• Do not prescribe oral TXA to women using hormonal contraceptives - the combination increases thrombotic risk 8
• Do not use IV TXA intrathecally - serious adverse reactions including seizures occur with wrong route 8
• Do not exceed 3-month treatment without ophthalmologic evaluation 8
• Adjust dose in renal impairment: Use 10 mg/kg twice daily if creatinine 1.36-2.83 mg/dL 8

Evidence Quality Note

The 2025 guideline evidence [5-5] focuses primarily on comparing PRP to TXA, consistently showing PRP superiority. However, for practical melasma management in women of childbearing age, oral TXA remains the most evidence-based, accessible, and cost-effective option when contraindications are absent 2, 3, 4. The intradermal route provides an excellent alternative when systemic therapy is contraindicated 9, 10.